Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
NCT05316116Phase 1Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of siltuximab in large granular lymphocytic leukemia (LGLL), sponsored by Moffitt Cancer Center. Primary endpoint: Overall Response Rate up to 30 months. Started Feb 2023; status: terminated.
02
Drugs
siltuximab
03
Conditions
large granular lymphocytic leukemia (LGLL)
Beyond the preview
Go deeper on NCT05316116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316116.